STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] OCULAR THERAPEUTIX, INC SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Ocular Therapeutix (OCUL) filing a Form 144 notifies the proposed sale of 10,502 common shares with an aggregate market value of $115,889.57. The shares were acquired on 10/01/2025 through restricted stock vesting under a registered plan, and the proposed approximate sale date is 10/02/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing reports 173,995,221 shares outstanding for the issuer. It also discloses a recent sale by the same person: 3,063 shares sold on 08/25/2025 for $36,882.81. The filer affirms they are not aware of any undisclosed material adverse information.

Positive

  • 10,502 shares were acquired by restricted stock vesting under a registered plan (compensation-related origin)
  • Filer affirms no knowledge of undisclosed material adverse information

Negative

  • Proposed sale of 10,502 shares with aggregate market value $115,889.57
  • Recent prior sale of 3,063 shares on 08/25/2025 for $36,882.81

Insights

TL;DR: Insider plans to sell 10,502 vested shares worth $115,889.57; prior sale of 3,063 shares noted.

The Form 144 shows an insider sale authorization for 10,502 common shares acquired by restricted stock vesting on 10/01/2025, with an approximate sale date of 10/02/2025 via Morgan Stanley Smith Barney LLC.

The filing also records a prior disposition of 3,063 shares on 08/25/2025 that generated $36,882.81 in gross proceeds. The issuer's reported outstanding share count is 173,995,221, which provides context for the scale of these transactions relative to total shares.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the OCUL Form 144 disclose?

The filing notifies a proposed sale of 10,502 common shares valued at $115,889.57, acquired via restricted stock vesting on 10/01/2025, with an approximate sale date of 10/02/2025.

Who is handling the sale in the OCUL Form 144?

The broker listed is Morgan Stanley Smith Barney LLC, with the sale planned on NASDAQ.

Has the insider sold other OCUL shares recently?

Yes. The filing reports a prior sale of 3,063 shares on 08/25/2025 that produced $36,882.81 in gross proceeds.

How many OCUL shares are outstanding per this filing?

The filing reports 173,995,221 shares outstanding.

When were the shares to be sold acquired?

The 10,502 shares were acquired on 10/01/2025 by restricted stock vesting under a registered plan.
Ocular Therapeut

NASDAQ:OCUL

OCUL Rankings

OCUL Latest News

OCUL Latest SEC Filings

OCUL Stock Data

2.58B
206.52M
3.33%
90.81%
7.95%
Biotechnology
Pharmaceutical Preparations
Link
United States
BEDFORD